SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is dominating conversations following reports of record-breaking vehicle deliveries for December and the fourth quarter, fueling strong community speculation about the company achieving its first profitable quarter. The electric vehicle maker's performance, alongside extended government subsidies for new energy vehicles in China, is generating bullish sentiment regarding its growth trajectory and competitive position against rivals. Despite some investor concern about market volatility, many remain focused on NIO's operational advancements.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is actively trending after a competitor's Cushing's syndrome treatment received a regulatory decline, clearing a significant market hurdle for Xeris's approved drug, Recorlev. The community is buzzing about this as a massive tailwind, expecting substantial market share gains that bolster XERS's already strong financial performance and promising pipeline. Analysts are reflecting this positive outlook, highlighting the company's compelling growth trajectory.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems (OSS) is trending due to the definitive sale of its Bressner Technology subsidiary for $22.4 million, a strategic move by management to focus on its higher-growth Edge AI compute business and strengthen its balance sheet. The community is actively discussing this, alongside strong anticipation for an imminent multi-hundred-million dollar US Army situational awareness contract, seeing OSS as significantly undervalued within the defense and AI sectors.

The Goldman Sachs Group, Inc. engages in the provision of financial services. It operates through the following business segments: Global Banking and Markets, Asset and Wealth Management, and Platform Solutions. The Global Banking and Markets segment includes investment banking, global investments, and equity and debt investments. The Asset and Wealth Management segment relates to the direct-to-consumer banking business which includes lending, deposit-taking, and investing. The Platform Solutions segment includes consumer platforms such as partnerships offering credit cards and point-of-sale financing, and transaction banking. The company was founded by Marcus Goldman in 1869 and is headquartered in New York, NY.

Goldman Sachs Group, Inc.

Goldman Sachs is drawing significant attention following robust Q3 earnings and strategic moves to bolster its ETF business through acquisitions, alongside its prominent role in a rebounding M&A market. The community is actively discussing the stock's impressive run and strategic AI integration efforts, with many anticipating continued strength, while others debate its high valuation and the potential for a stock split.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending sharply higher following the FDA's acceptance of its sNDA for AXS-05 in Alzheimer's disease agitation with Priority Review, setting a PDUFA target in April 2026. This significant regulatory clarity, coupled with positive updates for AXS-12 in narcolepsy and continued strong Auvelity script growth, is fueling widespread optimism among investors. The community is celebrating substantial long-term gains and actively discussing AXSM's potential to become a major CNS powerhouse, anticipating further analyst upgrades and robust performance as the company advances its diverse pipeline and commercial footprint.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bear 3X Shares

LABD, a leveraged inverse biotech ETF, is trending as the underlying XBI index continues an unexpected and sustained rally. This upward momentum, frequently attributed to recent sector buyouts and broader market sentiment regarding potential rate cuts, is causing significant frustration and deep losses for investors betting against the sector despite extreme overbought conditions.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics is trending following mixed interim Phase 2 results for its ARCT-032 cystic fibrosis therapy, which showed signs of mucus plug reduction but limited lung function improvement, leading to significant stock volatility. Community sentiment is divided, with many viewing the sharp decline as an overreaction and highlighting the therapy's biological activity, the strength of their mRNA platform, other pipeline assets, and a high-stakes trade secret lawsuit against AbbVie as key discussion points for future value. Simultaneously, discussions around their influenza vaccine candidates are gaining traction amidst concerns over emerging flu variants.

Tidal Trust II - Defiance Daily Target 2x Long SMCI ETF

Defiance Daily Target 2X Long SMCI ETF

SMCX is trending as its community grapples with the impact of a recent dividend distribution, leading to widespread confusion and frustration over its sharp decline. Many investors are questioning why the 2x leveraged ETF is not tracking its underlying asset, SMCI, as expected, fueling concerns about decay and the potential for a reverse split. While some traders see the current suppressed levels as a buying opportunity, others warn of the significant volatility and risks inherent in such leveraged products.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending amidst intense community debate around its price trajectory as the year concludes. While many express significant frustration over sustained losses and question its future, a strong contingent remains optimistic, urging others to 'buy the dip' and anticipate a substantial rebound in the upcoming year. Discussions also highlight year-end tax selling and the impact of a recent Doge giveaway, adding to its current volatility.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending after its relacorilant drug for Cushing's syndrome received a Complete Response Letter from the FDA, requesting additional efficacy evidence despite a successful pivotal trial, causing a sharp stock decline. Many investors view this over 50% drop as an overreaction, highlighting the company's established, revenue-generating drug Korlym and its broader pipeline. Amidst year-end tax-loss selling and wider biotech sector volatility, community discussion centers on the potential for regulatory resolution versus further valuation adjustments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Peloton Interactive, Inc. (<a class="mention" data-mention="$PTON" data-symbol-id="PTON" href="https://stocktwits.com/symbol/PTON" target="_blank">$PTON</a>) surged nearly 12% on Friday, drawing the attention of retail investors as well.As of 11:00 AM ET, PTON ranked among the top five trending tickers on Stocktwits, with retail sentiment shifting to ‘extremely bullish’ (88/100) from ‘neutral’ the day before.<figure class="image"><a href="https://stocktwits.com/symbol/PTON"><img style="aspect-ratio:1322/328;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_18_at_9_10_46_PM_416dabc0ee.png" alt="Screenshot 2024-10-18 at 9.10.46 PM.png" width="1322" height="328"></a><figcaption>PTON sentiment and message volume on Oct 18, as of 11:45 am ET | source: Stocktwits</figcaption></figure>Peloton announced that it will release its fiscal Q1 2025 results before the U.S. stock market opens on Thursday, Oct. 31. The company will host a conference call and live audio webcast to discuss the results at 8:30 AM.According to The Fly, bullish option activity was noted on Thursday, with 43,026 call options traded — twelve times the expected volume — leading to a 25-point increase in implied volatility, now at 133.49%.The most active options included the Nov-24 $6 calls and Oct-24 $5.5 calls, with total volume in these strikes approaching 17,300 contracts. The Put/Call Ratio stands at 0.04.Analysts predict Peloton will report a Q1 loss of $0.15 per share, an improvement from the $0.44 loss recorded in the same period last year.Revenue is expected to decline to $573.26 million, down from $595.5 million year-over-year.In August, Peloton posted Q4 results indicating its first quarterly revenue growth in 2.5 years, driven by a 2% increase in app subscription sales, which offset a 4% decline in hardware product revenue.Despite these signs of recovery, Peloton faces challenges, including ongoing dips in sales of its signature bikes and treadmills, declining expectations for hardware and app subscribers amid economic uncertainties, and the search for a permanent CEO.Market optimism has bolstered following recent management developments.Earlier this month, Peloton announced a partnership with Truemed, which allows eligible U.S.-based customers to use pre-tax Health Savings Account (HSA) and Flexible Spending Account (FSA) dollars to purchase Peloton products at attractive prices.BMO Capital has maintained a ‘Market Perform’ rating with a $6.50 price target on Peloton, noting that recent meetings with the company’s management were “upbeat.”The discussions highlighted a balanced focus on sustainable profits while exploring growth opportunities, including Peloton’s new and improved product offerings like Strength+ (a collection of strength training programs and classes), pricing strategies, cost savings, instructor initiatives, and the ongoing CEO search.So far this year, PTON stock has declined by over 0.15%.Read next: <a href="https://stocktwits.com/news-articles/markets/equity/aapl-stock-rises-after-positive-china-data/cJ22j6bRI8">Apple Stock Perks Up On iPhone China Sales Report: Retail Optimism Rises</a>

Peloton acknowledged ongoing challenges: sales of signature bikes and treadmills continued to dip. Photo courtesy: Peloton

Peloton Stock Gains Momentum, Retail Attention As Earnings Near: Here’s What Analysts Expect

Peloton announced that it will release its fiscal Q1 2025 results before the U.S. stock market opens on Thursday, Oct. 31.

Equity

Peloton Interactive Inc (PTON) shares soared as much as 28% on Thursday, marking their biggest one-day jump in over a year after the company's quarterly earnings report, which hinted at a potential comeback.Retail investors turned ecstatic, driving the sentiment score on Stocktwits to ‘extremely bullish’ (94/100) – the highest level this year.<figure class="image"><a href="https://stocktwits.com/symbol/PTON"><img style="aspect-ratio:1320/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/PTON_sentiment_and_message_volume_Aug_22_6751a22665.png" alt="PTON sentiment and message volume Aug 22.png" width="1320" height="318"></a><figcaption>PTON sentiment and message volume Aug 22</figcaption></figure>This earnings report, the first since former CEO Barry McCarthy stepped down earlier this year, offered some positive signs for Peloton's turnaround strategy led by two board members.Sales finally increased for the first time in nine quarters, indicating an end to the downward trend. June-quarter losses significantly shrunk by 87% to $30.5 million, showcasing progress towards profitability.The key subscription segment saw a 2.3% revenue rise and a 1% point improvement in gross margin. Peloton generated positive free cash flow of $26 million, compared to negative figures in previous quarters.Still, Peloton acknowledged ongoing challenges: sales of signature bikes and treadmills continuing to dip; expectations of hardware and app subscribers declining based on economic uncertainties; and the ongoing hunt for a permanent CEO.Despite these hurdles, retail investors on Stocktwits expressed strong confidence in Peloton's future.<stembedurl>https://stocktwits.com/Furgersen7/message/583788877</stembedurl>They praised the company's cost-cutting measures and focus on cash flow generation.<stembedurl>https://stocktwits.com/mulder35/message/583776075</stembedurl>Some even compared Peloton's potential turnaround to the recent success story of Carvana, the used-car retailer that reported its first-ever annual profit earlier this year and has since been on a mission to strengthen its balance sheet.<stembedurl>https://stocktwits.com/Tigerrouse111/message/583790791</stembedurl>In the coming months, investors are likely to keep an eye on Peloton's ability to retain and grow its subscriber base, the impact of the broader economic climate on consumer spending and the appointment of a new CEO in the coming months.But for now, they have regained full confidence in the stock that last saw its heyday during the COVID-19 pandemic in 2021.&nbsp;&nbsp;&nbsp;&nbsp;

Peloton Stock Rallies On Turnaround Signs, Retail Investors Turn ‘Extremely Bullish’

PTON stock surged after better-than-expected earnings, which highlighted a decrease in losses, growth in the subscription segment, and improved cash flow.

Current Price	$46.92
Prev Close	$47.20
Open	$47.08
Dividend Yield	N/A
50-Day Moving Average	$46.93
Beta	N/A
Avg. Volume	6,195.95
PE Ratio	N/A

52-Week High	$50.86
52-Week Low	$36.87
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

MILN
Global X Funds - Global X Millennial Consumer ETF

Feed

News

Sentiment

Fundamentals

Info

Latest MILN News

MILNGlobal X Funds - Global X Millennial Consumer ETF